AstraZeneca (LSE:AZN) Stock Looks Cheap On Cash Flow While Broader Checks Stay Mixed
AstraZeneca stock has delivered a 73.3% return over the past five years, yet current valuation checks suggest the market price may still sit below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) model and earnings multiples. With fresh headlines around cancer drug developments and mixed analyst views, investors are weighing whether that apparent discount fairly reflects the company’s growth prospects and risks.
- Over five years, AstraZeneca shares are up 73.3%, which already rewards long term holders and raises the bar for any further value on offer.
- The recent positive regulatory opinion for Enhertu in HER2 positive metastatic breast cancer can support long term revenue expectations, while clinical trial setbacks and pipeline execution risk may still limit how much of that potential the market is willing to price in.
- The stock screens as undervalued on both a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples, yet the broader checks show a mixed picture rather than a clear bargain, with AstraZeneca scoring 4 out of 6 on valuation.
The issue now is whether AstraZeneca’s share price already reflects most of the long term upside that the intrinsic value work points to, or if there is still a meaningful margin between market price and fundamentals.
Find out why AstraZeneca's 18.0% return over the last year is lagging behind its peers.
Is AstraZeneca Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach values AstraZeneca on the cash it is expected to generate for shareholders over time. AstraZeneca’s latest twelve month free cash flow sits at about US$7.6b, and the model assumes those cash flows continue growing rather than shrinking, which supports a higher intrinsic value than would a flat or declining profile.
On these assumptions, the 2 Stage Free Cash Flow to Equity model points to an intrinsic value of about £227 per share. That implies the current share price sits roughly 43% below this estimate, so the stock screens as undervalued on a pure cash flow basis. The recent positive Committee for Medicinal Products for Human Use opinion for Enhertu in HER2 positive metastatic breast cancer helps explain why cash flow projections remain supportive even if market pricing is more cautious.
Putting it together, AstraZeneca stock currently appears undervalued relative to what its projected cash flows suggest.
Our Discounted Cash Flow (DCF) analysis suggests AstraZeneca is undervalued by 43.0%. Track this in your watchlist or portfolio, or discover 8 more high quality undervalued stocks.
Is AstraZeneca a Bargain on Earnings?
The P/E ratio is a useful way to think about AstraZeneca because earnings per share remain a central focus for many investors in large pharmaceutical stocks. AstraZeneca currently trades on a P/E of about 25.5x. That sits above the wider pharmaceuticals industry average of roughly 20.8x and also ahead of a peer group average of about 12.4x.
A fair P/E multiple that adjusts for AstraZeneca’s size, margins and risk profile is estimated at around 39.6x. On that yardstick, the current 25.5x reading indicates the stock trades at a discount to what this model suggests could be reasonable for the business, even after accounting for sector norms.
On this earnings multiple, AstraZeneca stock appears to be priced below this model’s estimate of a fair valuation.
See what the numbers say about this price — find out in our valuation breakdown.
The AstraZeneca Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where AstraZeneca's valuation puzzle leaves off, by spelling out what would need to happen to AstraZeneca's growth, margins and earnings for the stock to be worth materially more or less than today's price, and they sit on the company's Community page. Each Narrative links a fair value estimate to a clear story about AstraZeneca's possible catalysts and risks, so you can watch over time which version of events is closest to reality.
AstraZeneca attracts sharply different readouts from the community, with some investors focused on pipeline driven upside while others fixate on pricing pressure and trial risk.
Bull case: 22% undervalued
"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is expected by some investors to deliver multiple blockbuster launches over the next several years…"
Read the full Bull Case to see why AstraZeneca could be undervalued
Bear case: 9% overvalued
"The looming expiration of patents on key blockbuster drugs like Tagrisso, Farxiga, and Imfinzi is viewed by some investors as exposing AstraZeneca to biosimilar and generic competition that is almost certain to erode high-margin revenue streams…"
Read the full Bear Case to see why AstraZeneca could be overvalued
Do you think there's more to the story for AstraZeneca? Head over to our Community to see what others are saying!
The Bottom Line
AstraZeneca looks undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the tailored earnings multiple, although the wider set of checks points to a mixed overall picture rather than a straightforward bargain. The key question is whether the current discount reflects overly cautious sentiment or fairly prices the execution and pipeline risks that the community keeps flagging. What matters most from here is whether AstraZeneca can translate its late stage pipeline and existing franchises into resilient cash flows that support the current valuation without leaving investors stuck in a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com